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A frameshift Variant in the CHST9 
Gene Identified by Family-Based 
Whole Genome Sequencing Is 
Associated with Schizophrenia in 
Chinese Population
Jingchun chen1, Jain-Shing Wu1, travis Mize1,2, Marvi Moreno1, Mahtab Hamid1, 
Francisco Servin1, Bita Bashy1, Zhongming Zhao3,4, Peilin Jia3, Ming T. Tsuang5, 
Kenneth S. Kendler6, Momiao Xiong7 & Xiangning chen8
Recent studies imply that rare variants contribute to the risk of schizophrenia, however, the exact 
variants or genes responsible for this condition are largely unknown. In this study, we conducted whole 
genome sequencing (WGS) of 20 Chinese families. Each family consisted of at least two affected siblings 
diagnosed with schizophrenia and at least one unaffected sibling. We examined functional variants 
that were found in affected sibling(s) but not in unaffected sibling(s) within a family. Matching this 
criterion, a frameshift heterozygous deletion of CA (–/CA) at chromosome 18:24722722, also referred 
to as rs752084147, in the Carbohydrate Sulfotransferase 9 (CHST9) gene, was detected in two families. 
This deletion was confirmed by PCR-based Sanger sequencing. With the observed frequency of 0.00076 
in Han Chinese population, we performed both case-control and family-based analyses to evaluate its 
association with schizophrenia. In the case-control analyses, Chi-square test P-value was 6.80e-12 and 
the P-value was 0.0008 after one million simulations. In family-based segregation analyses, segregation 
P-value was 7.72e-7 and simulated P-value was 5.70e-6. For both the case-control and family-based 
analyses, the CA deletion was significantly associated with schizophrenia in the Chinese population. 
Further investigation of this gene  is warranted in the development of schizophrenia by utilizing larger 
and more ethnically diverse samples.
Schizophrenia is a complex psychiatric disorder with high heritability and complex genetic architecture1. To 
elucidate the etiology of this disease, much emphasis has been placed on the detection of common risk variants 
through genome-wide association studies (GWASs). To date, more than 100 loci have been found to be signif-
icantly associated with schizophrenia2. However, common variants such as single nucleotide polymorphisms 
(SNPs) are unable to account for all of the heritability. In fact, the variants identified by GWASs only provide an 
estimated heritability of approximately 7%3, suggesting there is still large missing heritability to be discovered. 
In addition, most of the individual genes from these common SNPs do not convey a direct risk for the disease. 
On the other hand, there is evidence that rare variants, such as rare SNPs with minor allele frequency (MAF) less 
than 0.01 and copy number variations (CNVs), have substantially larger effects on schizophrenia1. It is believed 
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that genes from those rare variants often confer a clear risk to the disease, which may potentially lead to the iden-
tification of novel treatment targets. With the advancements of genomic technology, whole genome sequencing 
(WGS) is widely accessible and has become the most invaluable tool for identifying rare SNPs and CNVs in com-
plex diseases, such as schizophrenia. This approach is especially powerful to detect rare variants in family-based 
studies with cases cluster over unrelated case-control studies, where disease-causing rare variants may be seen 
only once or twice among tens of thousands of subjects4, though such family samples might be difficult to collect.
In this family-designed study, we applied WGS to 20 Chinese families, each of which consisted of at least two 
affected siblings, one unaffected sibling, and one parent. In the initial analyses, we were only interested in func-
tional variants, such as frameshift mutation, that were found in the affected sibling(s) but not in the unaffected 
sibling(s) in a family. The variants meeting this criterion were then matched across families.
Seven frameshift mutations were found to meet the specified criteria. Among them, a variant at CHST9 was 
first selected to further investigate due to its previously reported association with schizophrenia via CNVs5. We 
reported here that a novel frameshift deletion (–/CA, heterozygous) from CHST9 gene was detected at chromo-
some 18:24722722 based on gnomAD database (http://gnomade.broadinstitute.org) (dbSNP ID: rs752084147, 
c.50_51delTG, p.Val17AlafsTer19). We observed this deletion in three children with schizophrenia from two 
independent families; none of the unaffected children were found to have the deletion. One parent from one of 
the two families, not diagnosed with schizophrenia but with another mental illness, also had this deletion. The 
deletion was confirmed by PCR-based Sanger sequencing in all four subjects. Statistical analyses from both the 
case-control and family-based analyses indicated that the CA deletion from CHST9 gene was significantly associ-
ated with schizophrenia in the Chinese population.
Results
Whole genome sequencing summary. Summary statistics of the WGS were listed in Table 1. The median 
depth of sequencing was 35.34 x and the median coverage was 99.69%, meeting the target sequencing depth of 
30 x. On average, each subject had > 680 million reads, 3.1 million SNPs, 430,000 indels, and 579,000 structural 
variants (SVs).
Family kinship analysis and aneuploidy analysis. The centered IBS method6 was followed to verify 
family relationship using 250,000 variants shared between the 101 subjects sequenced in this study. Aneuploidy 
analysis was also conducted utilizing the BCFtools package to confirm the gender of each individual7. In the 
family kinship analysis, two subjects (02C11277 and 01C05768) were removed from further examination as they 
were found to be unrelated to any of the other 99 subjects in this study (see Supplementary Table S1). One affected 
subject (01C07598) was originally assigned to Family 35-02497 but actually belonged to Family 35-39622, leaving 
Family 35-02497 with only one affected and one unaffected subject. Subject 01C08839 with missing age was listed 
as the mother of Family 35-4560, however, kinship analysis indicated that she was more likely to be the daughter 
of this family. Referring back to the original family data, indeed, the family had a 47-year-old daughter who was 
never diagnosed with a psychiatric illness. 01C08839 was, therefore, assigned as an unaffected daughter in this 
family. For all other subjects, family relationships were confirmed by kinship analysis. The sex of all subjects was 
also confirmed with the prediction from BCFtools package. The kinship matrix was listed in Supplementary 
Table S1, and the sample description and results from sex prediction were listed in Supplementary Table S2.
Frameshift mutations and CHST9 deletion. Using the strategies described in the Selection of poten-
tial risk variants under Materials and Methods, we generated a variant list that included the variants only pres-
ent in affected sibling(s), but not in the unaffected sibling(s). Parents were excluded from the initial analyses. 
Supplementary Table S3 showed the number of functional annotations before and after filtering. Only 27.37% 
of total variants and 19.66% of variants from exons remained after filtering. Frameshift insertions and deletions 
(indels) are coding variants that cause amino acid changes from the variant site onward. This type of variant 
was the primary target of this study due to the likely functional alteration of their coded proteins. In total, seven 
frameshift indels were identified in two or more families (Table 2). Among these variants, the two-base-pair 
deletion at chr18:24722722 in the CHST9 gene was of special interest as it was the only gene reported to be asso-
ciated with schizophrenia in a previous study5. In that report, a CNV of CHST9 was found to be associated with 
schizophrenia. From a gene dosage perspective, loss-of-function (LoF) from a frameshift deletion could have 
similar effects as to those resulting from a loss of copy number. To further assess whether or not this mutation was 
de novo, the binary sequence alignment map (BAM) files were visually inspected using the IGV software (http://
software.broadinstitute.org/software/igv/)8,9. All 99 subjects were examined at this location, including the parents. 
With the IGV analysis, the father of Family 35-13523, who had an affected son with this deletion, was also found 
Raw data # of Reads Variants identified
Raw data size Raw depth Coverage
Total Mapped Duplicated SNP InDel SV(GB) (x) (%)
Median 102.28 35.34 99.69 6.69E + 08 6.68E + 08 1.21E + 08 3.11E + 06 4.29E + 05 5.60E + 03
Average 103.69 35.83 99.40 6.80E + 08 6.79E + 08 1.22E + 08 3.11E + 06 4.30E + 05 5.79E + 03
SD 8.39 2.90 0.36 5.52E + 07 5.50E + 07 3.97E + 07 2.79E + 04 1.32E + 04 1.48E + 03
Table 1. Whole genome sequencing summary statistics. Abbreviations: GB: gigabyte; SD: standard deviation; 
SNP: single nucleotides polymorphism; InDel: insertion and deletion; SV: structural variant.
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to have the same deletion (Fig. 2). Although the father was not diagnosed with schizophrenia, he was diagnosed 
with a non-specified mental illness (Table S2). The mother, who was never diagnosed with any psychiatric illness, 
did not have the deletion at this locus. As this deletion was found in the father of Family 35-13523, the variant 
was excluded as a de novo mutation. In Family 35-02478, two affected children, one son and one daughter, had 
the deletion, while the father, who was never given a diagnosis of any psychiatric illness, did not have the dele-
tion. No clinical data or DNA was available for the mother of this family. Due to the extremely low probability of 
having the exact same de novo mutation occur twice within two independent families in a single generation, it 
was concluded that the mutation was likely inherited from the mother. In total, our WGS analysis identified four 
subjects that had the heterozygous frameshift deletion (–/CA) in the CHST9 gene. Of these four individuals, three 
were affected children with schizophrenia from two independent families, and one was a parent diagnosed with 
a mental illness other than schizophrenia. Our results indicated that not all of the affected children from these two 
families had this mutation, implying that other genetic, or environmental factors might also play a significant role 
in the development of this disease. It should be noted that the CHST15 gene was also considered a potential target 
as it belongs to the same family as the CHST9 gene. The variant in CHST15 contained 13 or more homopolymeric 
G region, which made the call of exact variants difficult from Sanger sequencing. More time is required to follow 
up with this gene. Among the other genes listed in Table 2, their functions were largely unknown, except that 
SHCBP1L (SHC binding and spindle associated 1 like), a gene that has been reported to play an important role in 
spermatogenesis in mammals10.
As shown in Supplementary Tables S4 and S5, other variants, such as stop-loss and stop-gain, were also sum-
marized as they might also dramatically change the protein functions. Among these variants, 15 genes were 
reported to be associated with schizophrenia. These variants are potential targets for future investigations.
Sanger sequencing verification of the CHST9 deletion. PCR-based Sanger sequencing was used to 
confirm the CHST9 mutation as described in Materials and Methods. All members from Family 35-13523 and 
Family 35-02478 were subjected to verification. The four subjects found to have the CA deletion from WGS 
Figure 1. A flow chart of the WGS analysis study.
# Gene Frameshift Chr Position RS# Allele MAF Fam# ProteinChange Function
1 PRAMEF12 insertion 1 12837705 rs199736234 G/GCC 0.00314 2 p.Leu474CysfsTer2 unknown
2 SHCBP1L deletion 1 182908602 rs202104189 AAATT/A 0.00192 2 p.Asn285CysfsTer58 spermatogenesis
3 PRR21 deletion 2 240982059 rs755088823 CCGTGGGTG/C 0.10073 2 p.Phe111LeufsTer268 unknown
4 PRR21 deletion 2 240982229 rs866295021
GTGGGTGAAGA 
GCCGTGGATGA 
AGGGCCA/G
0.01128 2 p.Met48ThrfsTer329 unknown
5 POLN deletion 4 2074702 rs3833632 TG/T 0.00680 2 p.Gln837SerfsTer8 unknown
6 CHST15 insertion 10 125780762 rs200905582 G/GGGGC 0.00154 3 p.Pro453AlafsTer54 sulfotransferase
7 CHST9 deletion 18 24722722 rs752084147 GCA/G 0.00020 2 p.Val17AlafsTer19 schizophrenia
Table 2. Frameshift mutations observed in two or more families. Abbreviations: Chr: chromosome; Fam#: 
numbers of family detected; MAF: minor allele frequency.
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analysis were all confirmed with Sanger sequencing. Therefore, the results of Sanger sequencing were 100% con-
cordant with the results of WGS. Figure 3A shows a representative chromatography of Sanger sequencing for a 
normal sequence and a heterozygous CA deletion sequence.
Association analysis of CA deletion in CHST9 with schizophrenia in the Chinese population. In 
this study, we conducted WGS with a family design in 20 Chinese families. For association analyses, two differ-
ent approaches were conducted in this study. One approach was based on a case-control assumption where the 
affected individuals or risk allele carriers were considered as cases and compared to the general Han Chinese 
population. Here we conducted a Chi-square test with Yates’ Correction to compare the frequency of potential 
risk variants with the MAF from large exome and genome sequence databases, such as the Genome Aggregation 
Database ([GnomAd], http://gnomad.broadinstitute.org/)11, Exome Aggregation Consortium ([ExAC], http://
exac.broadinstitute.org/)11, and the Chinese Gene Mutation Database [CNGMD v.5.0] (http://cngmd.virgilbio.
com/). As different databases had reported different MAF for this deletion, we believed that the general Han 
Chinese population from CNGMD v.5.0 database was the best reference for our Han Chinese families. We con-
sidered that the subjects in our WGS study were either high-risk carriers (parents) or cases (children with schizo-
phrenia), whereas the subjects from these databases were general population controls. Under this assumption, we 
conducted a Chi-square test with Yates’ Correction. Given the frequency of 0.00076 in the general Han Chinese 
from CNGMD v.5.0 database, the results showed that there was a significant association between this deletion and 
schizophrenia in the Chinese population (P = 2.15e-6 for the carrier group, and P = 6.80e-12 for the case group). 
Since the CA deletion was a rare variant, we further conducted simulations to evaluate its association with schizo-
phrenia. We used the simulation function as implemented in the MonteCarlo R package and performed 1 million 
simulations for the Chi-square test for the high-risk carrier and case groups separately. The results remained 
significant (P-values were 0.0032 and 0.0008, respectively for the carrier and case groups). In addition, we also 
conducted the association tests using the MAF information from the larger databases (gnomAD and ExAC) as 
references. The association P-values for the carrier and case groups varied from 0.0046 to 1.90e-75. More details 
of the results were shown in Table 3.
Another approach was family-based association analyses. In these analyses, we used the gene-based segrega-
tion method (GESE)12 that assumed Mendelian segregation and 100% penetrance. With the observed frequency 
of 0.00076 in Han Chinese population, we first estimated the segregation probabilities for the two families (Family 
35-13523, P-value = 0.0012 and Family 35-02478, P-value = 0.0006, respectively), and then obtained the joint seg-
regation probability for the two families (P-value = 7.72e-7). With 10,000,000 simulations, the joint segregation 
probability was 5.70e-6.
Overall, both the Chi-square and family segregation test from the family-designed study on the 20 Chinese 
families indicated that the frameshift CA deletion was significantly associated with schizophrenia in the Chinese 
population.
Discussion
In this study, we attempted to identify rare variants/genes associated with schizophrenia in the Chinese popu-
lation using a family-based WGS approach. We found a two-base-pair CA deletion in the CHST9 gene in three 
schizophrenia cases from two independent families. One parent, who was not diagnosed with schizophrenia, but 
had another mental illness, was also found to have this deletion. Two different approaches were used to evaluate 
the association of this deletion with schizophrenia. In the case-control approach, Chi-square tests with Yates’s cor-
rection and permutation showed a significant association between the CA deletion and schizophrenia. In the sce-
nario where schizophrenia patients were compared to the reference population, the P-values were 6.80e-12 and 
Figure 2. Pedigrees of Family 35-02478 and Family 35-13523. Circles and squares denote females and males, 
respectively. A black box represents an affected subject. A cross inside the shape denotes that the individual was 
not diagnosed with schizophrenia but with another mental illness. An arrow indicates the proband of the family. 
A question mark represents that the individual’s DNA was unavailable. A red circle outside the shape means the 
individual had the two base pair CA frameshift deletion in the CHST9 gene.
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0.0008 for Chi-square and permutation tests, respectively. We made an arguement that this scenario was more 
appropriate as we were directly comparing schizophrenia cases to the healthy general population. Even in the sce-
nario where we treated the parents as high-risk carriers, we found that the CA deletion was still significantly asso-
ciated with schizophrenia (P-values were 2.15e-6 and 0.0032 for Chi-square and permutation tests, respectively). 
With the family-based segregation analyses (GESE), the joint segregation P-value for the two families was 7.72e-7. 
Simulated P-value for the segregation was 5.70e-6. Under the assumption of Mendelian segregation and 100% 
penetrance, the GESE12,13 could be used to jointly evaluate multiple mutations in a single gene for association 
with the disease of interest, given the observed frequencies in the general population. Although schizophrenia is 
a complex disorder with incomplete penetrance, the segregation analyses are still appropriate. Overall, in either 
the case-control or segregation analyses, we found that the CA deletion in CHST9 gene from our family study was 
associated with schizophrenia in the Chinese population. However, the study does have some limitations: (1) The 
sample size in this study is relatively small. Despite that we have observed the association, further studies with 
larger samples are need to validate our results. (2) Our study only includes those from the Chinese population. 
Incorporating different ethnic groups may provide more insights for its association with the disease.
Carbohydrate sulfotransferase 9 (CHST9) gene (HGNC ID: 19898; Entrez Gene: 83539; Ensembl: 
ENSG00000154080; OMIM: 610191), located on human chr18q11.22 (genomic location: chr18: 24495595–
24765302, reference genome GRCh37/hg19), contains five exons with a total gene length of about 270 kb. The 
cDNA encodes a type II membrane protein with 443 amino acids (AA) that belong to the sulfotransferase 2 fam-
ily. This protein is localized to the Golgi membrane and is thought to catalyze the transfer of sulfate to position 
four of the non-reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans and O-glycans14,15. Thus, 
it is also referred to as GALNAC4ST-2 or GALNAC-4-ST2. In humans, it is highly expressed in the trachea, but 
is also expressed in the brain, particularly in the hippocampus and hypothalamus16. The sulfate groups on car-
bohydrates confer highly specific functions to glycoproteins, glycolipids, and proteoglycans17 that are critical for 
cell-cell interaction, signal transduction, and embryonic development18.
As shown in Fig. 3B, the CHST9 protein contains a 12-AA cytoplasmic domain, a 21-AA transmembrane 
domain (TM), and a 410-AA luminal domain19. Evidence has shown that the luminal domain of the protein 
contains four potential N-linked glycosylation sites and two motifs: putative 5′-phosphosulfate-binding site 
(5′-PSB) and 3′-phosphate-binding site (3′-PB) of 3′-phosphoadenosine-5′-phosphosulfate (PAPS)19. The first 
two domains play an important role in substrate recognition, whereas the last domain holds the sulfotransferase 
that mainly catalyzes the transfer of sulfate as mentioned above. The TM domain also plays essential roles in 
anchoring and stabilizing the protein to the membrane.
The two-base-pair frameshift deletion of CA at chr18:24722722 is located in the first exon of the CHST9 gene. 
This variant, a c.50_51delTG based on NM_031422.5, is predicted to result in a truncated protein (p.Val17A-
lafsTer19) that consists of only 34 AA. More importantly, the mutation starts at the 17th AA in the TM domain, 
where Valine (Val) was substituted with Alanine (Ala) followed by an additional 17 new residues. The protein 
sequence changes derived from the CA deletion suggest that the truncated protein is highly likely to lose the 
major functions of the protein, including recognizing the substrates, anchoring the protein to the membrane, 
and transferring a sulfate group to other proteins. As such, this variant should be classified as an LoF mutation, a 
category that includes nonsense, frameshift, splicing acceptor, and splicing donor variants. It is possible that the 
loss of function of the CHST9 protein may interfere with normal brain development, and thus contribute to the 
development of schizophrenia. More specifically, the loss of the chondroitin 4-sulphotransferase activity might be 
critical in the process of disease development. Indeed, studies have shown that well-organized perisynaptic aggre-
gates, known as perineuronal nets (PNNs), were formed by the extracellular matrix (ECM), where chondroitin 
sulfate proteoglycans (CSPGs) are the primary components20–24. Studies have also indicated that PNNs play a 
critical role in neural patterning, synaptic signaling, plasticity and neuroprotection during postnatal development 
and adulthood. Therefore, the LoF mutation in CHST9 may change the normal structures and functions in CSPGs 
or PNNs. As a result, it may interfere with brain development and cause neural malfunction and diseases, such as 
schizophrenia and other psychiatric disorders25–29. In addition, evidence also showed that the formation of these 
Database Population AlleleCount Allele# Allele freq
Scenario 1 Scenario 2
Chiq.P-Val SIM.P-Val Chiq.P-Val SIM.P-Val
gnomAD
East Asian 49 19476 2.52E-03 4.56E-03 0.01827 1.52E-05 0.00489
South Asian 3 30210 9.93E-05 2.16E-38 0.00005 1.90E-75 0.00002
overall 54 279362 1.93E-04 9.72E-32 0.00012 2.32E-62 0.00004
ExAC
East Asian 23 8626 2.67E-03 7.67E-03 0.02219 4.29E-05 0.00593
South Asian 2 16510 1.21E-04 1.15E-26 0.00013 4.98E-52 0.00004
overall 25 120728 2.07E-04 1.42E-28 0.00018 4.87E-56 0.00004
CNGMD
Han_Chi(CHH, CHS, CHB) 4 5254 7.61E-04 2.15E-06 0.00321 6.80E-12 0.00080
overall 11 7352 1.50E-03 2.54E-04 0.00823 6.31E-08 0.00213
Table 3. Association analyses of the CA deletion with various populations as references. Abbreviations: 
Chiq.P-Val: P-value from Chi-squared test; CNGMD: Chinese Gene Mutation Database; ExAC: The Exome 
Aggregation Consortium; Freq.: frequency; gnomAD: Genome Aggregation Database. Han_Chi: all Han 
Chinese in the CNGMD database, including CHH (Han Chinese in China), CHS (Han Chinese in the South 
of China), and CHB (Han Chinese in Beijing). SIM.P-Val: P-value computed by Monte Carlo simulation when 
setting the number of replicates B = 1,000,000.
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specialized ECM aggregates was associated with distinct populations of GABAergic interneurons and that CSPG 
abnormalities were found in several brain regions of patients with schizophrenia29. Interestingly, we identified 
another variant at rs200905582 (chr10:125780762) in CHST15 gene (Table 2), which also belongs to a gene family 
encoding membrane-bound sulfotransferases as CHST9 gene does30. This result suggested that proteins with 
sulfotransferases might be important in schizophrenia. Further studies on these proteins, gene-set or pathway 
analysis might provide more insights to understand the pathophysiological roles in human diseases.
Direct evidence for the functional impact of CHST9 has not been reported thus far. In the literature, there was 
one report that schizophrenia was associated with CNV of CHST931, where patients exhibited a slight increase in 
genome doses of CHST9. A similar result was also reported for autism32. In this study, the CA deletion of CHST9 
gene is significantly associated with the diagnosis of schizophrenia. The bioinformatic analysis further suggests 
that the truncated protein caused by the CA deletion of this gene would lose its major function as a sulfate trans-
ferase. As it currently stands, it is unclear how this gene may contribute to schizophrenia.
In addition to psychiatric disorders, CHST9 CNVs were also found to be associated with acute myelogenous 
leukemia (AML)33, as well as other types of hematologic malignancies34, suggesting that CHST9 may play a role 
in the development of hematologic malignancies. CHST9 has also been linked to the development of breast can-
cer35,36 and gastric cancer37. Further examination of this gene is warranted to better understand the function 
of this gene, as well as the genetic basis and molecular pathogenesis of schizophrenia and other diseases. More 
thorough functional studies on this gene may lead to a novel target for the treatment of these disorders, espe-
cially schizophrenia for Chinese patients.
Materials and Methods
Subjects. The subjects of a single ethnicity (Taiwanese Han Chinese) were recruited in the Taiwan 
Schizophrenia Linkage Study (TSLS) from 1998 to 2002. Detailed information has been described previously38,39. 
Briefly, families with at least three siblings, two of whom were diagnosed with schizophrenia, were recruited. All 
enlisted subjects were interviewed using the Diagnostic Interview for Genetic Studies (DIGS)40, accompanied by 
the Family Diagnostic Interview for Genetic Studies (FIGS) (https://www.nimhgenetics.org/interviews/figs/). The 
final diagnostic assessment was based on the criteria of the fourth edition of the Diagnostic and Statistical Manual 
(DSM-IV), joined with the record of DIGS, FIGS, interviewer notes, and hospital anamnesis. Whole blood 
samples were collected and sent to the National Institute of Mental Health (NIMH) Repository and Genomics 
Resource (RGR) to be transformed into lymphoblastoid cell lines and stored. DNA samples extracted from the 
cell lines were used for WGS. Twenty Chinese families (total of 101 subjects) were selected from the TSLS. The 
Figure 3. Sanger sequencing of normal and affected individuals, and structure of the human CHST9 gene and 
coded protein. (A) Sanger sequencing of normal and affected individuals. The –/CA variant identified was 
verified via Sanger sequencing. Sequence from an unaffected child was clean and matched to the sequence 
from the human genome browser GRCH37/hg19. The sequence with the heterozygous deletion from an 
affected child showed double peaks immediately after the CA deletion. The red arrow indicated the locus of 
deletion. (B) Structure of the human CHST9 gene and coded protein. Upper panel shows the five exons that 
are transcribed into the coding sequence (black boxes) from the 5′ to 3′ direction. Exons are numbered from 
1 (E1) to 5 (E5). Bottom panel, the translated CHST9 protein is shown. TM denotes the transmembrane 
domain. Putative binding sites for the 5′-phosphosulfonate group (5′-PSB) and 3′-phosphate group (3′-PB) of 
3′-phosphoadenosine-5′-phosphosulfate (PAPS) are marked. Truncated protein caused by the deletion in this 
study is indicated in red.
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selection criteria were that each family had (1) at least two affected siblings, (2) at least one unaffected sibling at 
the age of 32 or older, and (3) at least one of the parents. Of these 20 families, eight had both parents, whereas 
the remaining 12 had only one parent. Two subjects were excluded after kinship analysis6, as they did not belong 
to any of the 20 families, resulting in 99 subjects for the final analysis. Informed consent was obtained from all 
participants and/or their legal guardians for the original study and the study reported herein was approved by 
the Institutional Review Board at Virginia Commonwealth University as it was initially started there, and then 
transferred to University of Nevada, Las Vegas. All methods were performed in accordance with the relevant 
guidelines and regulations.
WGS, variant calling, and annotation. WGS was carried out on the Illumina HiSeq. 2000 platform using 
paired-end chemistry with 75 base-pair read length through NovoGene (Beijing, China). NovoGene conducted 
first-round quality control, removed adapter sequences, and pruned low-quality reads. Once the FASTQ files 
were received from NovoGene, the Genome Analysis Toolkit (GATK, version 3.7) best practices pipeline41–43 was 
followed to process the sequence reads (see Fig. 1 and Supplementary Descriptions S6). Briefly, any remaining 
Illumina adapter sequences were removed via Picard, and reads were aligned utilizing the Burrows-Wheeler 
Aligner. Individual sample variants were called by the GATK HaplotypeCaller function, then joint genotyp-
ing was performed through the use of GATK’s GenotypeGVCFs to produce a multi-sample variant call format 
(VCF) file. GRCh37/hg19 was used as the human reference genome. Second-round quality filtering, such as 
removing residual low-quality reads, base quality score recalibration, and variant quality score recalibration were 
accounted for in the various preprocessing tools of GATK’s best practices pipeline. All VCF files were annotated 
with ANNOVAR44 to extract functional annotation and GATK’s VariantAnnotator to extract variant annota-
tion. Interactive Genome Viewer (IGV) (http://software.broadinstitute.org/software/igv/)8,9 was used to visually 
inspect the called variants. The whole genome sequencing project PRJNA551447 generated during the current 
study in the format of fastq files have been deposited at the National Center for Biotechnology Information 
(NCBI) repository.
Polymerase chain reaction (PCR)-based Sanger sequencing validation. For the families where 
candidate variants were found, DNA from all members of the family was subjected to PCR-based Sanger sequenc-
ing by capillary electrophoresis according to standard molecular biology practices (ABI 3130 genetic analyzer, 
ThermoFisher Scientific). Primer3Plus45,46 was used to design the PCR primers. For the CHST9 deletion, the 
forward primer sequence was 5′-AAGAAAAAGCACATGTGTTA-3′ and the reverse primer sequence was 
5′-CAGATGGCTGCATTTCTCCT-3′. Reactions were performed on an Eppendorf MasterCycler (Eppendorf 
North America, New York, USA) under the following cycling conditions: denaturation at 95 °C for 2 min, 30 
cycles of 95 °C for 15 sec, 55 °C for 30 sec, 72 °C 30 sec, and an extension with 72 °C for 5 min. Sanger sequencing 
data was then analyzed using Chromas software47 (https://seqcore.brcf.med.umich.edu/sites/default/files/html/
interpret.html).
Selection of potential risk variants. Potential risk variant discovery was performed utilizing the follow-
ing procedure. First, all variants that were found to only occur in affected sibling(s), but not in the unaffected 
sibling(s), within a single family, were retained while all other variants were removed. The retained variants were 
considered to have the potential to be associated with the disease within a family. Second, these variants were then 
matched across families. Variants found in two or more families were selected as candidates for further analyses. 
Third, variants were classified based on their genomic functions, such as exonic, intronic, etc. In this analysis, 
coding variants that resulted in a change of amino acid, i.e. non-synonymous SNPs, and frameshift insertions and 
deletions (indels), were the primary focus. Fourth, Sanger sequencing was used to verify the frameshift mutations. 
Fifth, association analyses were conducted using a Chi-square test with Yates’ correction and Monte Carlo sim-
ulation test. Verified potential risk variants were compared to the MAF from large exome and genome sequence 
databases (See details in Section of Satatistical analyses). We proposed that the subjects in our WGS study were 
either high-risk carriers (parents) or cases (children with schizophrenia), whereas the subjects from these data-
bases were general population controls.
Statistical analyses. Two approaches were used in this study. The first was a case-control approach where 
the Chi-square test was used. We used the R function chisq.test to conduct a Pearson’s Chi-square test with 
Yates’ Correction and Monte Carlo simulation test48. This test calculated the difference of the allele frequencies 
between the cases (subjects with schizophrenia) or carriers (parents of cases) and controls (general population 
from databases, such as gnomAD, ExAC, and CNGMD v.5.0, as mentioned above). The frequency of the variant 
at rs752084147 varies among different databases from different populations. According to the initial study, all of 
the 20 Taiwan families belong to Han Chinese population38,39, therefore, the general Han Chinese from CNGMD 
v.5.0 database were deemed to be the best reference as the control. In the CNGMD v.5.0 database, the deletion 
frequency of rs752084147 in the Han Chinese population was 0.00076 (4 alleles from 5254 alleles). We used this 
frequency as the reference for control in the latter Chi-square test. Here, although each family had 2 or more 
affected individuals, we only counted as one case in each family. This was because these siblings were related; 
variants shared between the affected siblings were likely transmitted from the same parent. Based on our study 
design, two scenarios were considered to assess the frequency of the CA deletion in the 20 families. Scenario 1: 
Considering the parents of these 20 families as a high-risk population (carriers), we compared their allele counts 
with the general Han Chinese population. Under this condition, there was a total of 80 effective alleles in the 40 
potential carriers (20 families, each contributed 4 alleles). Therefore, allele counts from the carrier group were 
counted 2 alleles with CA deletion among total 80 alleles. Scenario 2: Considering the affected subjects of the 20 
families as cases, we compared their allele counts with the general Han Chinese population. In Scenario 2, we 
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could count a total of 40 effective alleles in the 20 cases (20 families, each family contributed 2 alleles). Again, 
we only counted one case in each family for the reason mentioned above. Therefore, allele counts from the case 
group were 2 alleles with CA deletion among total 40 alleles. Scenario 2 was a direct comparison between case and 
control, thus, we believed it was more appropriate.
The second approach was a family-based segregation analysis. Here we used the R package of Gene-based 
Segregation Test (GESE) method reported by Qiao et al.12,13 under the assumption of Mendelian segregation and 
100% penetrance. In this method, multiple mutations in a single gene could be jointly evaluated for association 
with the disease of interest given the observed frequencies in the general population. The segregation analyses 
are also appropriate even though schizophrenia is a complex disorder with incomplete penetrance. Therefore, we 
used it to estimate the segregation probability for the families given the CA deletion frequency observed in the 
Han Chinese population, and used simulations to assess the association with schizophrenia.
Data Availability
The whole genome sequencing project PRJNA551447 generated during the current study in the format of fastq 
files have been deposited at the National Center for Biotechnology Information (NCBI) repository (https://data-
view.ncbi.nlm.nih.gov/object/PRJNA551447?reviewer=sorlv9h1kc2d2sa358m70br0pu). All the datasets will be 
available on 2019-08-12 or upon publication, whichever is first.
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